UnitedHealth (NYSE:UNH) Beats Q1 2026 Estimates, Raises Full-Year Guidance

Recent Developments

UnitedHealth Group (NYSE: UNH) reported first-quarter 2026 results that exceeded analyst expectations on both the top and bottom lines. Revenue came in at $111.7 billion, up 2% year over year, according to reporting by Yahoo Finance. Non-GAAP earnings per share reached $7.23, coming in 9.4% above the analyst consensus estimate.

Alongside the results, UnitedHealth raised its full-year 2026 adjusted earnings guidance to more than $18.25 per share, up from its prior forecast of more than $17.75 per share, according to Yahoo Finance. The company attributed the improved outlook to strong cost management and continued strategic investments.

One analyst description cited by Yahoo Finance characterized the report as "arguably best print in a couple years," reflecting broad positive reception on Wall Street following the release.

Financial Snapshot

UnitedHealth Group shares closed at $353.91, up $30.43, or 9.41%, on the day. The previous close stood at $323.48. The stock's 52-week range spans $234.60 to $489.79, placing the current price roughly in the middle of that band.

The Q1 revenue figure of $111.7 billion and non-GAAP EPS of $7.23 both cleared consensus estimates, with the earnings beat of 9.4% representing a notable outperformance relative to expectations.

Wall Street View

Analyst sentiment toward UnitedHealth remains broadly positive. As of April 1, 2026, the consensus recommendation breakdown stands at 6 Strong Buy, 18 Buy, 8 Hold, 1 Sell, and 1 Strong Sell. That compares with a prior-period breakdown from March 1, 2026, of 6 Strong Buy, 17 Buy, and 9 Hold, indicating a modest shift toward Buy-rated coverage and a slight reduction in Hold ratings. Analyst price target data is not currently available.

Key Takeaways

• UnitedHealth reported Q1 2026 revenue of $111.7 billion, up 2% year over year, and non-GAAP EPS of $7.23, beating consensus by 9.4%.
• The company raised its full-year 2026 adjusted EPS guidance to more than $18.25, up from more than $17.75 previously.
• Shares rose $30.43, or 9.41%, to $353.91, against a 52-week range of $234.60 to $489.79.
• Analyst consensus as of April 1, 2026, leans heavily toward Buy, with 24 out of 34 rated analysts holding Buy or Strong Buy recommendations.